The FAST™ System has the Potential to Expedite ID & AST for Bloodborne Pathogens from Positive Blood Cultures  
Presented by: David Pride, MD, PhD

Infectious Disease Specialist
UC San Diego Health

Moderated by: Dr. David Haake Chief Medical Officer at Qvella

Join David Pride, MD, PhD as he discusses how the high morbidity and mortality of sepsis is positively impacted by improved technologies to expedite identification (ID) and antibiotic susceptibility testing (AST) of causative bacteria. We are evaluating the Qvella FAST™ System which creates a Liquid Colony™ (LC) from a Positive Blood Culture (PBC) that can be used for downstream applications and potentially expedite ID and AST results in comparison to standard of care (SOC). Our preliminary beta study results indicate that the FAST™ System could provide a LC for definitive IDs and ASTs from PBCs with minimal errors. The FAST™ System can accelerate workflow in processing downstream applications by 24-48 hours compared to SOC.

Learning Objectives:

  • • Become familiar with the Qvella FAST™ System
  • • Introduce the concept of Liquid Colony™
  • • Identify potential strengths and weaknesses of the Qvella FAST™ System compared to standard of care at most institutions
  • • Identify workflow changes involved in adopting Liquid Colony™ technology
FAST™ System and FAST PBC Prep Cartridge have received CE marking for In-Vitro diagnostic (IVD) use in Europe (as per EU IVDR 2017/746) and are now listed as Class I IVD devices with the US FDA. These devices have not been validated for any downstream diagnostic applications and are only indicated for positive blood culture specimens containing bacteria. The user will be responsible for validating the system in combination with diagnostic procedures.